Table 2.

Molecular response and clinical outcome after GO



Results of qualitative RT-PCR for PML-RARα*





Patient no.
1st cycle
2nd cycle
3rd cycle
No. GO cycles received
Relapse/type
Duration of molecular remission, mos.
Successive therapies
Outcome
1   ND   Negative   Negative   3   No   31+   —   Alive in MR  
2   Negative   Negative   Negative   3   No   14+   —   Alive in MR  
3   Positive   Positive   —   2   Yes/morphologic   NE   MITOX, MITOX  Alive in MR  
4   Negative   Negative   Negative   3   Yes/molecular   13   GO/MITOX + ARA-C   Alive in MR  
5   Negative   Negative   Negative   3   Yes/morphologic   6   MITOX + ARA-C   Died of disease progression  
6   ND   Negative   Negative   3   No   7+   —   Alive in MR  
7   ND   ND   —   2   Yes/morphologic   NE   —   Died of disease progression  
8   Negative   ND   Negative   3   Yes/molecular   7   MITOX + ARA-C   Alive in MR  
9   ND   Negative   Negative   3   Yes/molecular   8   GO  Alive in MR  
10   ND   Negative   Negative   3   No   19+   —   Alive in MR  
11   Negative   —   —   1   Yes/molecular   6   DLI   Alive in MR  
12   ND   ND   Negative   3   No   12+   —   Alive in MR  
13   ND   ND   Negative   3   No   19+   DLI   Alive in MR  
14   ND   Positive   Negative   3   No   15+   —   Alive in MR  
15   ND   Negative   Negative   3   Yes/molecular   15   —   Alive in MR  
16
 
Negative
 
Negative
 
Negative
 
3
 
Yes/morphologic
 
3
 
ATO
 
Died of disease progression
 


Results of qualitative RT-PCR for PML-RARα*





Patient no.
1st cycle
2nd cycle
3rd cycle
No. GO cycles received
Relapse/type
Duration of molecular remission, mos.
Successive therapies
Outcome
1   ND   Negative   Negative   3   No   31+   —   Alive in MR  
2   Negative   Negative   Negative   3   No   14+   —   Alive in MR  
3   Positive   Positive   —   2   Yes/morphologic   NE   MITOX, MITOX  Alive in MR  
4   Negative   Negative   Negative   3   Yes/molecular   13   GO/MITOX + ARA-C   Alive in MR  
5   Negative   Negative   Negative   3   Yes/morphologic   6   MITOX + ARA-C   Died of disease progression  
6   ND   Negative   Negative   3   No   7+   —   Alive in MR  
7   ND   ND   —   2   Yes/morphologic   NE   —   Died of disease progression  
8   Negative   ND   Negative   3   Yes/molecular   7   MITOX + ARA-C   Alive in MR  
9   ND   Negative   Negative   3   Yes/molecular   8   GO  Alive in MR  
10   ND   Negative   Negative   3   No   19+   —   Alive in MR  
11   Negative   —   —   1   Yes/molecular   6   DLI   Alive in MR  
12   ND   ND   Negative   3   No   12+   —   Alive in MR  
13   ND   ND   Negative   3   No   19+   DLI   Alive in MR  
14   ND   Positive   Negative   3   No   15+   —   Alive in MR  
15   ND   Negative   Negative   3   Yes/molecular   15   —   Alive in MR  
16
 
Negative
 
Negative
 
Negative
 
3
 
Yes/morphologic
 
3
 
ATO
 
Died of disease progression
 

ND indicates not done; MR, molecular remision; NE, not evaluable; ATO, arsenic trioxide; DLI, donor lymphocyte infusion; and —, patient did not receive this treatment. See Table 1 footnote for other abbreviations.

*

In 4 cases, the material collected after the second GO dose was insufficient for RT-PCR analysis.

Patient received 3 additional GO doses.

Patient received 4 additional GO doses.

or Create an Account

Close Modal
Close Modal